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Abstract 
Introduction: Higher cortisol levels are associated with cardiovascular morbidity and mortality in the elderly, partially resulting from 
biologic effects of glucocorticoids (GCs) on endothelial cells observed in an experimental setting. These features are replicated in patients 
with endogenous GC excess (Cushing’s syndrome) or with exogenous hypercortisolism due to excessive pharmacological application of 
GCs. Both groups present also an increased cardiovascular disease event rate. GCs may also adversely influence recovery after myocardial 
infarction. Recently it was proposed that microRNAs (miRNAs) — small noncoding RNAs functioning as antisense regulators of gene 
expression by targeting mRNA — may have a central role in regulating endothelial function through multiple mechanisms. Thus, the 
purpose of this study was to evaluate the effects of chronic GC excess on the expression of selected endothelium-controlling miRNAs 
expressed in nucleated cells circulating in peripheral blood (PBNCs) of patients with endogenous hypercortisolism either due to cortico-
trophin‐independent or corticotrophin‐dependent Cushing’s syndrome (CS).
Material and methods: Peripheral blood nuclear cells were collected from 35 healthy subjects and 31 patients with endogenous hypercorti-
solism as a source of miRNAs. A self-validated individual quantitative RT-PCR study was then performed to evaluate the expression levels 
of selected miRNAs in PBNCs. Additionally, endothelin-1 (ET-1) expression in peripheral blood was assessed with respect to endothelial 
dysfunction using Western blotting. 
Results: The ET-1 expression levels in CS were higher than in controls, confirming endothelial dysfunction in the CS group. Furthermore, 
miRNA analysis revealed a significantly decreased intracellular expression of selected endothelium-related miRNAs in patients with 
endogenous hypercortisolism, including miRNA-17-5p, miRNA-126-3p, and miRNA-126-5p, compared to controls. In contrast, two other 
angiogenic miRNAs, miRNA-150-5p and miRNA-223-3p, were significantly upregulated compared to controls.
Conclusions: Cardiovascular events related to hypercortisolism remain a challenging problem in medical practice. This study has dem-
onstrated that the chronic excess of GCs in endogenous CS might induce significant dysregulation of selected miRNAs involved in the 
control of endothelium biology. However, the lack of knowledge about specific miRNA expression postpones the full understanding of the 
biological roles of such miRNAs in hypercortisolism. Moreover, dysregulated miRNAs seem to be promising targets for further research, 
especially to search for potential therapies for several GC-induced cardiovascular complications. (Endokrynol Pol 2019; 70 (6): 489–495)
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Introduction
Glucocorticoids (GCs) are used extensively to cure 
many diseases due to their anti-proliferative, immu-
nosuppressive, and anti-inflammatory effects [1]. Thus, 
synthetic GCs are widely used with multiple indications 
and many administration forms used for both systemic 
and local disorders, including inflammatory and auto-
immune diseases or haematological neoplasms. About 
1% of the general population are using long-term GC 
therapy at any given time, due to the increased preva-
lence of diseases requiring such therapy [2–3]. There is 
growing concern that markedly increased use of GCs 
can lead to supraphysiological GC exposure and may 
induce specific adverse cardio-metabolic complica-
tions, such as dyslipidaemia, adiposity and central 
obesity, decreased insulin sensitivity, hyperglycaemia 
and diabetes, inflammation, immune dysregulation 
and platelet activation, and finally hypertension and 
atherosclerosis followed by cardio-vascular derange-
ments, such as increased risk of coronary artery disease, 
heart insufficiency, or stroke [4–5]. These exogenous 
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would have some importance in the development and 
progression of GC-related cardiovascular complica-
tions. These small non-coding RNAs control gene 
expression by targeting messenger RNA (mRNA) and 
disturb translation, and thus represent a major class of 
molecular regulators. An increasing number of specific 
miRNA expression signatures have been identified in 
CVD, and they have gained importance in recent years 
by helping diagnosis as biomarkers. It has also been 
demonstrated that miRNAs influence various genes 
known to be associated with angiogenesis. “AngioMIRs” 
are a set of miRNAs that play important roles in the 
regulation of angiogenic responses and endothelial 
cell (EC) functions. For instance, the miRNA-126 fam-
ily, composed of two strands: miRNA-126-3p and 
miRNA-126-5p, is enriched in endothelial cells and is 
recognised as a leading regulator of angiogenesis and 
vascular integrity. The miRNA-126-5p strand promotes 
EC proliferation, improving re-endothelialisation after 
vascular injury [15]. In contrast, miRNA-126-3p inter-
feres with the process of EC activation by inhibiting 
the expression of VCAM-1 molecules and impeding 
leukocyte adhesion to ECs and their transmigration 
[16]. The miRNA-126 cluster is a master regulator in 
endothelial dysfunction as well. The level of both 
miRNA-126 (miRNA-126-3p and miRNA-126-5p) were 
lowered in diabetic patients, and their expression was 
reduced in EC exposed to high glucose in vitro [17]. Low 
levels of miRNA-126 in diabetic EC are associated with 
decreased proliferation, migration, and NO production 
[18]. These observations suggest a strong role of the 
miRNA-126 cluster in the modulation of atherosclerosis 
development and vascular complications in diabe-
tes. Other miRNAs shown to regulate angiogenesis, 
such as miRNA-17 cluster, are regulated by vascular 
shear stress and promote the growth of blood vessels 
[19]. Of note, blood levels of miRNA-17 and miRNA-126 
were decreased in stable coronary artery disease. Regu-
lation of EC function has also been demonstrated in 
the case of miRNA-150, which, secreted from activated 
monocytic cells, was able to enhance EC migration [20]. 
Other studies showed that levels of miRNA-150 were 
higher in patients with myocardial infarct and increased 
in response to inflammatory stimuli [21]. Likewise, 
miRNA-223, the expression of which is dependent on 
intracellular cholesterol levels, has also been reported 
to play a role in endothelium, especially due to the fact 
that miRNA-223 negatively regulates the inflammatory 
response by blocking the NLRP3 inflammasome and 
IL-1b production [22]. Altogether, it seems that the in-
volvement of miRNAs in angiogenesis and endothelial 
cell function in cardiovascular system is substantial, 
making miRNAs presumably major governing forces in 
the pathogenesis of endothelial dysfunction developing 
GC-related complications have been strictly linked 
to increased cardio-vascular morbidity or mortality 
[4–5]. Nevertheless, there is no medical consensus on 
the best strategies for the prevention and detection 
of GC-induced complications, and available data on 
these adverse events are rather poor, with many of the 
clinical studies being inconclusive, resulting in the lack 
of optimal treatment strategies for patients affected 
with glucocorticoid-induced adverse cardio-metabolic 
disorders.
Nonetheless, some of these questions can be 
answered by analysing available data from patients 
with hypercortisolism in the course of endogenous 
Cushing’s syndrome (CS), which is a model of the 
pathological state with extremely elevated cortisol 
levels. This is a condition characterised by excessive 
and continuous elevation of cortisol, usually caused by 
a pituitary or adrenal adenoma. It is known that ACTH 
and cortisol play a complex role in the regulation of 
carbohydrate, lipid, and protein metabolism, energy 
homeostasis, and the regulation of body fluids and body 
composition, all of them strongly related to vascular 
functions [6]. Thus, the excess of endogenous cortisol 
can lead to a variety of clinical manifestations, includ-
ing cardio-metabolic disorders. Although long-term 
elevated cortisol is an important cardiovascular risk 
factor and higher cortisol levels were associated with 
a higher incidence of cardiovascular diseases (CVD), 
the molecular mechanisms responsible for GC-induced 
cardiovascular complications are not well established. 
Several studies have suggested the crucial role of 
nitric oxide (NO), eicosanoids, and oxidative stress 
together with renin-angiotensin system alterations in 
haemodynamic changes in the cardiovascular system 
of patients with hypercortisolism [7]. Glucocorticoid 
overexposure leads to alterations in the cardiovascular 
system structure and function also via vasoconstrictor 
factor endothelin-1 (ET-1). It was demonstrated that 
GCs induce ET-1 release, and suppress the activity of 
the NO system and thus cause vasoconstriction result-
ing in endothelial dysfunction [8]. Related studies have 
also shown that endothelial dysfunction is involved 
in other GC-induced vascular pathologies including 
hypertension [9], myocardial failure [10], dyslipidaemia 
[11], and atherosclerosis [12]. The coexisting persistent 
inflammatory environment further contributes to eleva-
tion of ET-1 [13], endothelial dysfunction, and impaired 
endothelium-dependent relaxation, all contributing to 
the pathogenesis of cardiovascular complications [14]. 
Importantly, the mechanisms for the development 
and progression of cardio-metabolic complications and 
the markers for remission and recurrence have not been 
sufficiently investigated yet. Several studies suggested 
that epigenetic regulation based on microRNA (miRNA) 
491
Endokrynologia Polska 2019; 70 (6)
O
R
IG
IN
A
L
 P
A
P
E
R
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found in other diseases.
The purpose of the study was to evaluate intracel-
lular PBNC expression levels of five selected candi-
date “angioMIRs” that regulate various angiogenesis 
signalling pathways and endothelial dysfunction po-
tentially involved in the pathogenesis of GC-induced 
cardiovascular complications in patients with Cush-
ing’s syndrome. We advocate that CS, usually affecting 
young and presumably healthy patients, is a good in 
vivo model to examine the effects of GC excess on the 
expression of angiogenesis-related microRNAs known 
to affect endothelial cell homeostasis in human vascu-
lature, minimising other confounding factors including 
the disease itself, the dose and type of GC, as well as 
the compliance of the patients.
Material and methods
Characteristics of the study group
Thirty-one patients with hypercortisolism due to newly diagnosed 
endogenous Cushing’s syndrome (CS), as a result of either adreno-
cortical or pituitary tumours [23], were recruited in the Department 
of Endocrinology of the Pomeranian Medical University in Szczecin, 
Poland. The control group consisted of 35 age-matched participants 
with no symptoms or signs of CS (defined as the absence of typi-
cal clinical features of CS). All of the enrolled subjects underwent 
a complete medical examination for statistical analyses. Data 
regarding medical history, current drug use, and smoking status 
were collected based on laboratory data, pathology tests, and other 
information, with a particular focus on heart and vascular condi-
tions and existing arterial hypertension. The study adhered to the 
tenets of the Declaration of Helsinki, and approval was obtained 
from the Local Research Ethics Committee. Moreover, each patient 
provided written, informed consent for involvement in the study.
Blood sample collection
Venous blood samples (~7.5 mL) collected in EDTA tubes were 
centrifuged (2000 rpm, 4°C, 10 min), and the plasma was stored at 
−20°C to −80°C until assayed. Next, the red blood cells were lysed 
using BD Pharm Lyse lysing buffer (BD Biosciences, San Jose, CA, 
USA) for 15 min at room temperature to isolate peripheral blood 
nuclear cells (PBNCs).
Western blot analysis
The total protein concentrations were determined using the Brad-
ford protein assay (Sigma-Aldrich). Subsequently, the extracted 
proteins (20 μg/well) were separated on 14% gel (SDS-PAGE; Mini 
Protean Tetra Cell System; Bio-Rad). Fractionated proteins were 
transferred onto a 0.2-μm PVDF membrane (Bio-Rad), and the 
membranes were blocked with 3% bovine serum albumin (BSA) in 
buffer for one hour at RT. Endothelin-1 protein was detected using 
rabbit polyclonal IgG antibody (Santa Cruz Biotechnology) and 
goat anti-rabbit IgG with horseradish peroxidase as a secondary 
antibody (Santa Cruz Biotechnology). The membranes were devel-
oped with Western blot analysis (ECL Advance Western Blotting 
Detection Kit; Amersham Life Sciences, Buckinghamshire, UK), and 
bands were subsequently visualised (Gel DOC-It Imaging system; 
Bio-Rad, Hercules, CA). Equal loading in the lanes was evaluated by 
stripping the blots for two hours at 37°C and then overnight at RT 
(IgG Elution Buffer; Thermo Scientific, Rockford, IL) and re-probing 
them with GAPDH (goat polyclonal IgG) HRP-conjugated antibody. 
Protein levels were analysed densitometrically by ImageJ software.
MicroRNA analysis
MicroRNA for molecular analysis was obtained from peripheral 
blood nuclear cells (PBNCs). Cellular RNA was isolated from 3 × 106 
nucleated cells using the mirVana Isolation Kit with organic phenol 
extraction (Thermo Fisher Scientific, MA, USA) according to the 
manufacturer’s protocol. The RNA concentration was measured 
using an Epoch Microplate Spectrophotometer (BioTek, VT, USA), 
and 100 ng was used for first-strand cDNA synthesis. For cDNA 
synthesis, 4 μL of each sample was used. First-strand cDNA synthe-
sis was performed in all samples using a qScript microRNA cDNA 
Synthesis Kit (Quantabio, MA, USA). qPCR for the assessment of 
miRNA expression was performed with a Bio-Rad CFX96 Real-
Time Detection System (Bio-Rad, CA, USA). The reaction solution 
consisted of 1 μL of cDNA sample, iQ SYBR Green Supermix (Bio-
Rad, CA, USA), Universal Primer provided in qScript microRNA 
Synthesis Kit, and a forward primer specific to miRNA analysis. 
Quantification of the target microRNA expression value was ex-
pressed as 2‐Ct. To find the best reference gene, the NormFinder 
algorithm was used; miRNA-93 was set as a reference miRNA.
Statistical analysis
The arithmetic means and S.D.s were calculated on an IBM com-
puter using Statistica version 5.0 software (Chicago, IL, USA). Data 
are given mostly as the mean ± S.D., and were analysed using 
the Mann–Whitney U test. Statistical significance was defined as 
p < 0.05.
Results
In total, 66 subjects were evaluated. The Cushing’s syn-
drome (CS) and healthy control groups were matched 
for age and gender as well as well-known cardiovascu-
lar risk factors, including hypertension, history of isch-
aemic heart disease, myocardial infarct, cerebral stroke, 
peripheral artery disease, and aortic aneurysm. There 
were no significant differences in clinical characteristics 
between the study groups except for the existence of 
hypercortisolism in the former group.
Endothelial dysfunction marker analysis
Hypercortisolaemia is associated with increased risk 
of endothelial dysfunction. Endothelin-1 is a power-
ful vasoconstrictor peptide of small and large vessels, 
which also acts as a modulator of vasomotor tone. It 
was reported that in most CVD the circulating levels 
of ET-1 were increased, and ET-1 at elevated patho-
logical concentrations acts also as proinflammatory 
and promotes cell proliferation, and thus attributes to 
the development of atherosclerosis and hypertension. 
Many cardiovascular complications are associated with 
endothelial dysfunction, which is particularly defined 
as dysregulation of the vascular function associated 
with an imbalance in the close interdependence of NO 
and ET-1 [24]. Due to difficulties in NO measurement, 
the analysis of ET-1 is presumably a good marker of 
vascular endothelial dysfunction. Thus, taking into 
consideration its biological and pathophysiological 
significance, we first analysed the expression profile of 
ET-1 using anti-ET-1 antibody in plasma of peripheral 
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blood collected from all examined subjects. As shown 
in Figure 1, we observed significantly increased expres-
sion of ET-1 protein in CS patients compared to healthy 
controls. This result indicates that patients with CS 
recruited to this study could develop endothelial dys-
function, and thus potentially suffer from GC-induced 
cardiovascular complications. 
MicroRNA expression profiles
Next, we performed a quantitative analysis of the ex-
pression of the selected miRNAs in peripheral blood 
nucleated cells (PBNCs) of Cushing’s syndrome patients 
and controls using qRT-PCR. We chose a panel of five 
miRNAs (miRNA-17-5p, -126-3p, -126-5p, -150-5p, and 
-223-3p). Of the five analysed miRNAs, three microR-
NAs (miRNA-17-5p, -126-3p, and -126-5p) showed 
significantly lower expression, whereas two microRNAs 
(miRNA-150-5p and -223-3p) showed significantly high-
er expression in PBNCs circulating in the cardiovascular 
system of CS patients compared with the expression 
in these cells collected from control subjects (Fig. 2–6). 
These results indicate that selected “angioMIRs” are dif-
ferently expressed in CS patients and healthy subjects, 
which may be related to the developed endothelial 
dysfunction present in the former group.
Discussion
This is the first study evaluating both plasma ET-1 
expression profile and selected angiogenesis-related 
microRNA transcript quantification in cells circulating 
in PB from patients with active Cushing’s syndrome. 
The relationship between glucocorticoids and car-
diovascular disorders has been extensively studied, 
Figure 1. The expression profile of endothelium dysfunction-related molecule, ET-1, in peripheral blood from patients with Cushing’s 
syndrome and healthy controls. The protein expression of ET-1 was determined by Western blot (A). Protein bands obtained were 
analysed by densitometry (B). Bars represent mean ± standard deviation (SD) of selected protein to GAPDH ratios calculated in both 
examined groups. Representative images of the performed analyses are shown
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Figure 2. Cellular miRNA-126-3p profile in Cushing’s syndrome 
(CS) patients and controls. MiRNA-126-3p was significantly 
down-regulated in peripheral blood nuclear cells (PBNCs) collected 
from patients with CS compared to healthy volunteers. The results 
are expressed as the percentage of the control value taken as 100%. 
*p < 0.05 vs. control group
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Figure 3. Cellular miRNA-126-5p profile in Cushing’s syndrome 
(CS) patients and controls. MiRNA-126-5p was significantly 
down-regulated in peripheral blood nuclear cells (PBNCs) collected 
from patients with CS compared to healthy volunteers. The results 
are expressed as the percentage of the control value taken as 100%. 
*p < 0.05 vs. control group
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but with conflicting results. Some studies have shown 
that hypercortisolaemia is associated with increased 
cardiovascular morbidity and mortality, whereas other 
researchers cannot confirm this observation. Consis-
tent with the previous report [8], we found significant 
over-expression of ET-1 activity in the PB of CS patients, 
which presumably indicates an overall tendency for 
the development of endothelial dysfunction in the 
cardiovascular system of subjects with CS. Patients with 
endogenous CS are typically exposed to high cortisol 
levels for longer period of time than the usual duration 
of laboratory experiments and interventional studies 
in humans, which suggests that CS could be an ap-
propriate disease model in vivo that permits analysis 
of the influence of an excessive amount of GCs on the 
cardiovascular system and may potentially link it with 
GC-induced cardio-metabolic complications; thus, they 
could be adequately investigated. Moreover, it was re-
ported that there were no major differences between 
endogenous hypercortisolism in Cushing’s syndrome 
or diet-induced cardiometabolic disorders in terms of 
genetic cardiometabolic risk factors and regarding the 
pathogenesis of their complications [25].
We found that important “angioMIRs”, both 
miRNA-126-3p and miRNA-126-5p, were significantly 
downregulated in PBNC circulating in CS patients, 
which, according to the literature, may indicate de-
fective angiogenesis and reduced neovascularisation 
as miRNA-126 stimulates angiogenesis via VEGF 
signalling [26]. In animal models, areas of disturbed 
blood flow typically present the reduced miRNA-126 
expression associated with diminished endothelial 
cell proliferation [15]. Apart from endothelial cells, the 
miRNA-126 cluster plays additional roles in distinct cell 
types such as macrophages or endothelial progenitor 
cells circulating also in blood. In the latter, proangio-
genic activity is associated with increased expression 
levels of miRNA-126, and inhibition of this expression 
resulted in the restriction of their proangiogenic activity 
[27]. Moreover, it was reported that CD34+ cells, after 
high glucose treatment or isolated from DM2 patients, 
expressed lower miRNA-126 and impaired angiogenic 
properties that were recovered with miRNA-126 treat-
ment [27]. Besides, CD34+ cells from patients with 
cardiac insufficiency showed significantly lower expres-
sion of miRNA-126 [28]. Finally, the reduced miRNA-126 
levels in monocytes from DM2 patients were associated 
with increased tissue factor expression and higher 
pro-thrombotic activity [29]. It was also found that in-
tracellular miRNA-126 expressed in circulating platelets 
has also the potential to influence endothelial cells, 
stimulating their proliferation and inhibiting apoptosis 
Figure 4. Cellular miRNA-17-5p profile in Cushing’s syndrome 
(CS) patients and controls. MiRNA-17-5p was significantly down-
regulated in peripheral blood nuclear cells (PBNCs) collected from 
patients with CS compared to healthy volunteers. The results are 
expressed as the percentage of the control value taken as 100%. 
*p < 0.05 vs. control group 
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Figure 5. Cellular miRNA-150-5p profile in Cushing’s syndrome 
(CS) patients and controls. MiRNA-150-5p was significantly up-
regulated in peripheral blood nuclear cells (PBNCs) collected from 
patients with CS compared to healthy volunteers. The results are 
expressed as the percentage of the control value taken as 100%. 
*p < 0.05 vs. control group
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Figure 6. Cellular miRNA-223-3p profile in Cushing’s syndrome 
(CS) patients and controls. MiRNA-223-3p was significantly up-
regulated in peripheral blood nuclear cells (PBNCs) collected from 
patients with CS compared to healthy volunteers. The results are 
expressed as the percentage of the control value taken as 100%. 
*p < 0.05 vs. control group
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via AKT signalling pathway [30]. Consequently, the in-
tracellular downregulation of both miRNA-126-5p and 
miRNA-126-5p in circulating PBNCs from CS patients 
observed in our study are likely to contribute to the 
dysregulation of angiogenesis in this disease.
Consistent with previous findings in individuals 
with coronary artery disease and in patients with 
myocardial infarct [21], we determined that levels of 
miRNA-17 were significantly reduced and levels of 
miRNA-150 were upregulated in circulating PBNCs 
from CS patients compared to healthy subjects. The 
MiRNA-17 cluster controls the expression of VCAM-1, 
ICAM-1, and E-selectin, being involved in the coor-
dinated manner of regulation of the inflammatory 
response by the complex miRNA network in endo-
thelial cells that maintain intercellular communication 
with monocytic cells in the course of atherosclerosis 
[31]. Likewise, monocytes secrete miRNA-150, and its 
levels in microvesicles targeted towards endothelium 
increase in response to inflammatory stimuli present 
in atherosclerotic arteries [32]. The latter miRNA also 
showed the greatest discriminatory power for the di-
agnosis of unstable angina compared to patients with 
non-coronary chest pain or healthy subjects [20].
MiRNA-223 levels were also increased in circulat-
ing PBNCs from CS patients in our study. This finding 
is in accordance with previous studies demonstrat-
ing the significant role of intracellular miRNA-223 
that can be transferred from platelets to endothelial 
cells. It was shown that platelet miRNA-223 has the 
ability to target several genes, including B1-integrin, 
IGF-IR, and Fbxw7, which can regulate migration 
and angiogenesis [30]. Furthermore, miRNA-223 was 
shown to have a suppressive effect on macrophage 
proinflammatory activation, and miRNA-223-deficient 
macrophages exhibited increases in M1 and decreases 
in M2 polarisation biomarkers [33]. Our results are 
in line with another study by Zampetaki et al., who 
showed that miRNA-223, together with miRNA-126, 
has a high predictive value for risk of developing acute 
myocardial infarct, as a result of a 10-year follow-up 
prospective trial [34]. Consequently, our results in GC 
patients could be interpreted such that the increased 
level of miRNA-223 might represent attempts to com-
pensate for the above-mentioned negative effects of GC 
excess on endothelium-driven vascular homeostasis in 
a long-term exposure period in CS patients. 
Conclusions
This is the first study documenting the intracellular 
expression of “angioMIRs” in CS patients. There were 
significant differences in selected miRNA expression 
levels in nucleated cells circulating in the peripheral 
blood of CS patients compared to healthy subjects. This 
study enriches our understanding of differential expres-
sion of miRNA related to the control of the endothelium 
functions in the cardiovascular system of CS patients 
with typical cardio-metabolic complications, and may 
guide towards future therapeutic interventions. Nev-
ertheless, it requires further investigation.
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